Featured Research

from universities, journals, and other organizations

Gene Therapy Reversed Heart Damage In Rats With Heart Failure

Date:
December 31, 2008
Source:
Thomas Jefferson University
Summary:
Long-term gene therapy resulted in improved cardiac function and reversed deterioration of the heart in rats with heart failure, according to a recent study.

Long-term gene therapy resulted in improved cardiac function and reversed deterioration of the heart in rats with heart failure, according to a recent study conducted by researchers at Thomas Jefferson University's Center for Translational Medicine. The study was published online in Circulation.

The rats were treated with a gene that generates a peptide called beta ARKct, which was administered to hearts in combination with recombinant-adeno-associated virus serotype 6 (rAAV6). beta ARKct works by inhibiting the activation of G protein-coupled receptor kinase 2 (GRK2).

GRK2 is a kinase that is increased in heart failure myocardium. Enhanced GRK enzymatic activity contributes to the deterioration of the heart in heart failure, according to Walter J. Koch, Ph.D., the W.W. Smith Professor of Medicine and the director of the Center for Translational Medicine at Jefferson Medical College of Thomas Jefferson University. Dr. Koch's research team carried out the study, which was led by Giuseppe Rengo, M.D., a post-doctoral fellow.

"The theory is that by inhibiting this kinase, the heart will recover partially due to reversal of the desensitization of the beta-adrenergic receptors," Dr. Koch said. "The expression of beta ARKct leads to a negative neurohormonal feedback that prevents the heart from continuing on the downward slope during heart failure. This was one novel finding of the study."

Dr. Koch and his colleagues used five groups of rats in their study. Two groups received rAAV6 with the beta ARKct peptide, two groups received rAAV6 with green fluorescent protein (GFP), and the last group received a saline treatment. One of the beta ARKct groups and one of the GFP groups also received the beta blocker metoprolol concurrently.

Twelve weeks after receiving the treatment, the rats who received the beta ARKct had a significantly increased left ventricular ejection fraction. The treatment also reversed the left ventricular deterioration and normalized the neurohormonal status. Dr. Koch said that targeting the GRK2 enzyme with beta ARKct was sufficient to reverse heart failure even without concomitant metoprolol.

The rats that received GFP or saline alone experienced more deterioration of cardiac function during the course of the study. This deterioration was prevented, but not reversed, with the concomitant metoprolol.

"Our data show that beta blockers and the beta ARKct peptide are compatible and can be given together," Dr. Koch said. "Although beta blockers are effective at stopping the downward progression of the disease, they do not reverse the damage already done. That is where the beta ARKct gene therapy comes in."

In future trials in humans, the beta ARKct peptide will be administered with beta blockers, which are the standard treatment. However, Dr. Koch said that if a pharmaceutical inhibitor can be developed, then a new class of drugs to treat heart failure could possibly even replace beta blockers.


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Cite This Page:

Thomas Jefferson University. "Gene Therapy Reversed Heart Damage In Rats With Heart Failure." ScienceDaily. ScienceDaily, 31 December 2008. <www.sciencedaily.com/releases/2008/12/081229200746.htm>.
Thomas Jefferson University. (2008, December 31). Gene Therapy Reversed Heart Damage In Rats With Heart Failure. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2008/12/081229200746.htm
Thomas Jefferson University. "Gene Therapy Reversed Heart Damage In Rats With Heart Failure." ScienceDaily. www.sciencedaily.com/releases/2008/12/081229200746.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins